
    
      This is a double-blinded, placebo-controlled trial in men and women, 40-75 years old,
      diagnosed with pancreatic or cholangiocarcinoma cancer. Patients will receive placebo or
      sildenafil daily for 4 weeks during their initial chemotherapy cycle.
    
  